Insilicos Wins NIH Grant

Seattle, 15 April 2004 - Insilicos today announced that the National Institute of General Medical Sciences has awarded Insilicos an SBIR grant to apply Insilicos' proprietary extreme pattern recognition (XPR) techniques to single-cell proteomics. Insilicos President Erik Nilsson is PI on the grant.

In collaboration with Dr. Norman Dovichi's Laboratory at the University of Washington, Insilicos will apply XPR to the proteomes of individual Barrett's esophagus cells. Results of this research may have application to drug discovery, disease diagnosis, and basic research into mechanisms of cell maturation and dysplasia.

"Cell-resolution proteomics is a promising technique for exploring cellular mechanisms," said Nilsson. "But realizing this promise requires breakthrough instrumentation such as the Dovichi lab has developed, and breakthrough computational analysis, such as Insilicos' XPR."

"We're pleased to find people in the NIH who share our enthusiasm for this research," said Brian Pratt, Insilicos VP Development. "XPR is a remarkable technique for studying very large data sets, which opens a new window into molecular biology"

Insilicos LLC is a biomarker discovery and diagnostic development company, concentrating on cardiovascular disease.

For more information, visit the Insilicos web site www.insilicos.com or contact Insilicos at info@insilicos.com. 'Insilicos' 'PreClue," and 'Life Science Software' are trademarks of Insilicos LLC.